logo
#

Latest news with #CRISPR-based

UK government targets manufacturing as it eyes £41bn life science sector growth
UK government targets manufacturing as it eyes £41bn life science sector growth

Yahoo

time7 days ago

  • Business
  • Yahoo

UK government targets manufacturing as it eyes £41bn life science sector growth

The UK Government will enhance manufacturing and commercialisation as it looks to harness the value of the life sciences sector for the country's economy. In a new Life Sciences sector plan, the government outlined a six-point action plan to ensure the sector reaches its forecasted value increase of £41bn, representing a growth of 165% by 2035. The government is aiming to make the UK the leading life sciences economy in Europe, and third largest in the world behind only America and China. While excelling at research and development (R&D), the report outlines difficulties with commercialisation and adoption. For example, despite being the first country to approve a CRISPR-based medicine, Vertex and CRISPR Therapeutics' Casgevy for sickle cell anaemia is primarily commercialised overseas. In a bid to scale industry, the government has pledged £520m to improve life science manufacturing. Outlaid via the Life Sciences Innovative Manufacturing Fund (LSMIF), the investment will aim to expand the UK's manufacturing capabilities and supply chain security. The initiative comes at a crucial time, as British pharmaceutical companies are significantly increasing their investments in the United States. GSK invested $800m in drug substance and drug product manufacturing facilities in the US in October 2024. AstraZeneca – which has a market cap of £162bn – is reportedly plotting a move of its public listing to the US stock exchange in what would be a major blow to the UK economy. To facilitate the industry's expansion, the government will look to increase access to scale-up capital. There has been a cautious domestic investor base, leading to a lull in emerging companies with high economic outputs. The government will measure investment by the number of UK life science companies with a valuation of over £10bn, the number of companies on the FTSE 300, and the number of initial public offerings (IPOs) in the sector. From a regulatory standpoint, the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute of Care and Excellence (NICE) will be supported to provide faster approvals and more efficient reimbursement. Optimism and criticism for UK life sciences MHRA's chief executive Lawrence Tallon welcomed the news, saying: 'It's great to see the MHRA is recognised as a pivotal partner in delivering the plan's vision - by supporting innovation, protecting public health, and making the UK a global destination for innovators to research, develop and launch cutting-edge medical products.' David Stockdale, chief executive of the British Healthcare Trades Association (BHTA) highlighted the importance of reducing regulatory and financial barriers to accelerate faster delivery of innovative MedTech solutions to patients. "We welcome today's announcement which rightly aims to make the UK a leading hub for investment and innovation in lifesaving MedTech, an essential step if we are to improve patient care and cut down waiting times. We particularly welcome the renewed commitments to the Life Sciences Innovative Manufacturing Fund and the NHS Innovator Passports. Our members are eager to deliver their innovative products and services to patients more quickly and efficiently, and we look forward to working with the Government to make this a reality. Clinical trials are set to benefit from the plan, with a new 150 day or lower target for trial set up times. Finally, up to £600m will be put towards an artificial intelligence (AI)-ready health data platform, a strategy already launched in April 2025. The BioIndustry Association (BIA) said: 'The life science sector plan is right to focus on getting substantially more public and private investment in early-stage companies, improved access to data, trials and skills to help companies grow, and more streamlined regulation and market access pathways to get innovative medicines to NHS patients.' However, the Association of the British Pharmaceutical Industry (ABPI) commented that the plan falls short of investing in innovative medicines. Richard Torbett, Chief Executive of the ABPI, said: [The UK life sciences sector] has been struggling to remain competitive and attractive to investment. The solutions proposed are necessary and important, but they are not enough to turn around the UK's decline. 'The UK must address the core issue holding back the life sciences sector, the long-term disinvestment in innovative medicines that is increasingly preventing NHS patients from accessing medications that are available in other countries.' The life science sector plan comes hot on the heels of the 10-year health plan unveiled for the NHS earlier this month, which placed emphasis on technology and digitalisation. "UK government targets manufacturing as it eyes £41bn life science sector growth" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Integrated DNA Technologies Announces Translational CRISPR Portfolio Expansion with Product Innovation Updates
Integrated DNA Technologies Announces Translational CRISPR Portfolio Expansion with Product Innovation Updates

Business Wire

time7 days ago

  • Health
  • Business Wire

Integrated DNA Technologies Announces Translational CRISPR Portfolio Expansion with Product Innovation Updates

CORALVILLE, Iowa--(BUSINESS WIRE)--Global genomics leader Integrated DNA Technologies (IDT) is revolutionizing the field of translational gene editing with new additions to its end-to-end CRISPR portfolio. These expanded CRISPR translational research solutions are designed to help researchers accelerate more CRISPR-based therapies for patients like KJ Muldoon, an infant who suffered CPS1 deficiency and made history when he received the world's first personalized CRISPR therapy manufactured jointly by IDT and Aldevron. IDT provided the guide RNA (gRNA), off-target analysis services and regulatory support for baby KJ's treatment, which was delivered in a significantly compressed timeline. 'IDT's rich history, deep expertise, and ability to manufacture bespoke products at the highest quality uniquely positions us to consistently innovate on our CRISPR portfolio and support customers at every stage of their gene editing journey' Share Tailored gRNAs to Accelerate CRISPR Discoveries As researchers advance from discovery to clinical applications, the demand for higher purity in CRISPR reagents increases. To meet this need, IDT's chemically synthesized gRNAs are now available for online ordering in a range of modification and purity options. With high purity ideal for translational applications such as gene editing in primary cells and in vivo models, IDT's high-performance liquid chromatography (HPLC)-purified gRNAs are orderable in 2 nmol and 10 nmol yields with larger quantities available by request and ship in as little as 12 business days. Formats include CRISPR-Cas9 gRNA and Custom Alt-R™ CRISPR gRNA. 2' Fluoro, 2' O-Methyl, and other modifications can be added to increase stability and specificity with IDT's custom gRNA tool. Supporting Scientists with Regulatory Filings and Ensuring Safety of Therapeutic Candidates CRISPR-based genome editing allows for targeted editing at specific sites in the genome, but there is potential risk that off-target edits at other locations can occur. To enable scientists to understand where these off-target edits might happen and assess how they might impact safety early in the therapeutic development process, IDT launched UNCOVERseq, off-target nomination services which uses an enhanced GUIDE-seq™ methodology to identify off-target sites for its customers. When paired with IDT's award-winning off-target confirmation services, rhAmpSeq™ CRISPR Analysis System, CRISPR pioneers can confidently accelerate their path to the clinic by obtaining a deeper understanding of editing risks. The custom safety services provided in baby KJ's treatment helped launch UNCOVERseq and represent a major step forward in ensuring the safety of CRISPR-based therapies. Enhancing Safety, Quality and Efficiency: IDT's Growing Pipeline and Future Collaborations Future IDT launches, planned for late 2025, include complementary offerings such as the Alt-R HDR Enhancer Protein, which is designed specifically for therapeutic applications, and manufactured by Aldevron, to meet rigorous quality standards. The HDR Enhancer Protein improves HDR efficiency in difficult-to-edit cells, and maintains safety and cell health. IDT, in collaboration with Aldevron, will also be launching a novel Cas9 mRNA to support early discovery to clinical stage customers. IDT has been a long-time provider of CRISPR gRNA libraries for screening applications and will unveil a new design tool later this year for efficient ordering of custom, configured libraries. 'IDT's rich history, deep expertise, and ability to manufacture bespoke products at the highest quality uniquely positions us to consistently innovate on our CRISPR portfolio and support customers at every stage of their gene editing journey,' said Sandy Ottensmann, VP/GM, Gene Writing & Editing at IDT. 'On the heels of the world's first personalized CRISPR-based therapy, we're honored to bring more CRISPR tools that will enable researchers to make important discoveries, like the one designed for baby KJ, and progress science forward.' Learn more about IDT's CRISPR portfolio here. About IDT Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. For more information about IDT, visit and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram. Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations. Disclaimer: CGMP refers to products manufactured under ICHQ7; IDT engineering runs and CGMP gRNA are for development and investigational use only. The performance characteristics of this product have not been established. This product is not intended to be used as final drug product. The purchaser is solely responsible for all decisions regarding the intended use of the product and any associated legal or regulatory obligations. GUIDE-seq™ is owned by Maxcyte®, Inc.

The $20 Million Bet on CRISPR to Cure Rare Childhood Diseases
The $20 Million Bet on CRISPR to Cure Rare Childhood Diseases

Yahoo

time08-07-2025

  • Health
  • Yahoo

The $20 Million Bet on CRISPR to Cure Rare Childhood Diseases

Jennifer Doudna, Priscilla Chan Zuckerberg Credit - David Paul Morris—Bloomberg/Getty Images; Suzanne Cordeiro—AFP/Getty Images Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven't been many reliable treatment options for these babies. The few that do exist involve invasive and risky procedures that don't often have a high rate of success. But there is a new source of hope for many of these families: the Center for Pediatric CRISPR Cures at the University of California San Francisco. The center—plans for which were announced July 8—is a collaboration between Jennifer Doudna, director of the Innovative Genomics Institute at the University of California, Berkeley who also earned the Nobel Prize for her work in co-discovering the gene-editing technique CRISPR, and Dr. Priscilla Chan, co-CEO and co-founder of the Chan Zuckerberg Initiative. Supported by $20 million from the Chan Zuckerberg Initiative, the center focuses on treating rare genetic diseases in children, starting with a group of eight kids who will enroll in a clinical trial to access a CRISPR therapy designed specifically for them. Doctors and researchers, including Chan and Doudna, believe that CRISPR can be used to change and correct a range of genetic mutations and scaled up to help more patients. And the medical teams plan to start enrolling patients immediately. "We want to ensure that CRISPR-based therapies become widely available, especially for rare diseases that likely won't be the target for pharmaceutical companies," Doudna tells TIME. Read More: The 4 Words That Drive Your Doctor Up the Wall The partnership was inspired by the recent success in treating KJ Muldoon, the first baby to receive a customized CRISPR treatment. KJ was born at the Children's Hospital of Philadelphia with a rare genetic disease that prevents him from breaking down proteins properly. The therapy, called base-editing, replaced a faulty letter in KJ's DNA with the correct one that now lets him eat some protein. KJ's treatment represents the next phase of CRISPR-based therapies. While CRISPR treatments have been approved by the FDA to treat sickle cell disease and certain types of beta thalassemia, those therapies involve removing cells from patients, editing them with CRISPR to correct the genetic defect, and then infusing those cells back to the patients. In KJ's case, the CRISPR editing occurred in his own body, via three injections of a therapy developed just for him. That's the same model that the new center will use. 'With that story, there was a lot of momentum within our teams about whether we could do that again, and how we could learn from this to create a pipeline to reduce cost and make this therapy much more widely available,' Doudna says. Doudna thought of Chan, whose initiative has the mission of curing, preventing, or treating all diseases by the end of the century. It was an ideal match, since Chan had trained as a pediatrician at the University of California San Francisco and spent eight years treating children with rare genetic diseases after finishing medical school. 'When Jennifer called me, I thought, 'This is perfect,'' Chan tells TIME. She recalls encountering families whose babies were affected by diseases so rare that there was often little, if any, information about them. 'I have seared in my mind the image of a parent handing me a PDF that they carried around to explain to each resident that this is what we have, and this is all that we know about it. I carry that around daily.' The experience inspired her to create the Rare As One program at the Chan Zuckerberg Initiative, a network of patients, researchers, and scientists from different disciplines that highlights the need for basic research needed to better understand these conditions in order to develop more effective treatments for them. Read More: The Surprising Reason Rural Hospitals Are Closing CRISPR, with its ability to target specific genetic mutations, holds the most promise for changing the course of such diseases. But time is of the essence. In KJ's case, the entire process of identifying his mutation, developing the treatment, testing it, and receiving FDA clearance took nine months. KJ was just six months old when he received his first CRISPR treatment. Acting that quickly is critical for conditions like these, since once cells or organs are damaged by disease-causing mutations, they can't always be rescued. The idea is to intervene with a CRISPR therapy to minimize the effects that the mutations could have. Currently, about 6,000 rare diseases affect 300 million people worldwide, and 72% of them are linked to genetic aberrations. A similar proportion primarily affect children. The new center will focus on identifying disease-causing mutations that can easily be targeted—such as in the liver, as in KJ's case. 'Jennifer and her team, and the team at UCSF, will be very careful in choosing mutations that are amenable to this treatment,' says Chan. 'Not all mutations will work well with this version of there will be a delicate balance in choosing patients who stand to benefit the most in this situation.' Patients will join a clinical trial to receive the treatment, and the research team will study them to learn from their experiences and continue to improve the treatment and the process. Read More: Why It's So Hard to Have Your Fertility Tested In the first cases that the center will try to treat, the FDA will consider each treatment on its own and decide whether to approve the customized therapy for that particular patient. But, says Doudna, 'as we continue to get more information on the safety and potential risks of CRISPR for different indications, what is emerging is the potential to designate CRISPR as a platform technology.' That means that if regulators approve the framework of the CRISPR gene-editing process, doctors would not need to conduct animal tests for each new CRISPR therapy designed for a patient. The only thing that would change would be the guide RNA, Doudna says, which carries the genetic instructions for finding the specific mutation that needs to be addressed. 'Even there, most of the guide RNA stays the same, and it's just the piece at the end providing the molecular zip code that changes.' Key to making that happen will be advances in other scientific areas, including using AI to predict how changing specific genes will affect a cell's function and what potential health outcomes a CRISPR-based treatment might have. That work is ongoing separately at places like Chan Zuckerberg Initiative and elsewhere, says Chan. Eventually, says Doudna, 'we hope as the process moves forward, it will be possible to both predict clinical outcomes of CRISPR therapies accurately and ensure that by changing just a little part of the guide RNA, everything else will remain the same, so you don't have to do full-blown animal testing for every single iteration of CRISPR. If that becomes possible, then it will make CRISPR a lot cheaper and a lot faster to test these kinds of therapies.' That would make it available for many more patients as well. Contact us at letters@

The $20 Million Bet on CRISPR to Cure Rare Childhood Diseases
The $20 Million Bet on CRISPR to Cure Rare Childhood Diseases

Time​ Magazine

time08-07-2025

  • Health
  • Time​ Magazine

The $20 Million Bet on CRISPR to Cure Rare Childhood Diseases

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven't been many reliable treatment options for these babies. The few that do exist involve invasive and risky procedures that don't often have a high rate of success. But there is a new source of hope for many of these families: the Center for Pediatric CRISPR Cures at the University of California San Francisco. The center—plans for which were announced July 8—is a collaboration between Jennifer Doudna, director of the Innovative Genomics Institute at the University of California, Berkeley who also earned the Nobel Prize for her work in co-discovering the gene-editing technique CRISPR, and Dr. Priscilla Chan, co-CEO and co-founder of the Chan Zuckerberg Initiative. Supported by $20 million from the Chan Zuckerberg Initiative, the center focuses on treating rare genetic diseases in children, starting with a group of eight kids who will enroll in a clinical trial to access a CRISPR therapy designed specifically for them. Doctors and researchers, including Chan and Doudna, believe that CRISPR can be used to change and correct a range of genetic mutations and scaled up to help more patients. And the medical teams plan to start enrolling patients immediately. "We want to ensure that CRISPR-based therapies become widely available, especially for rare diseases that likely won't be the target for pharmaceutical companies," Doudna tells TIME. Read More: The 4 Words That Drive Your Doctor Up the Wall The partnership was inspired by the recent success in treating KJ Muldoon, the first baby to receive a customized CRISPR treatment. KJ was born at the Children's Hospital of Philadelphia with a rare genetic disease that prevents him from breaking down proteins properly. The therapy, called base-editing, replaced a faulty letter in KJ's DNA with the correct one that now lets him eat some protein. KJ's treatment represents the next phase of CRISPR-based therapies. While CRISPR treatments have been approved by the FDA to treat sickle cell disease and certain types of beta thalassemia, those therapies involve removing cells from patients, editing them with CRISPR to correct the genetic defect, and then infusing those cells back to the patients. In KJ's case, the CRISPR editing occurred in his own body, via three injections of a therapy developed just for him. That's the same model that the new center will use. 'With that story, there was a lot of momentum within our teams about whether we could do that again, and how we could learn from this to create a pipeline to reduce cost and make this therapy much more widely available,' Doudna says. Doudna thought of Chan, whose initiative has the mission of curing, preventing, or treating all diseases by the end of the century. It was an ideal match, since Chan had trained as a pediatrician at the University of California San Francisco and spent eight years treating children with rare genetic diseases after finishing medical school. 'When Jennifer called me, I thought, 'This is perfect,'' Chan tells TIME. She recalls encountering families whose babies were affected by diseases so rare that there was often little, if any, information about them. 'I have seared in my mind the image of a parent handing me a PDF that they carried around to explain to each resident that this is what we have, and this is all that we know about it. I carry that around daily.' The experience inspired her to create the Rare As One program at the Chan Zuckerberg Initiative, a network of patients, researchers, and scientists from different disciplines that highlights the need for basic research needed to better understand these conditions in order to develop more effective treatments for them. Read More: The Surprising Reason Rural Hospitals Are Closing CRISPR, with its ability to target specific genetic mutations, holds the most promise for changing the course of such diseases. But time is of the essence. In KJ's case, the entire process of identifying his mutation, developing the treatment, testing it, and receiving FDA clearance took nine months. KJ was just six months old when he received his first CRISPR treatment. Acting that quickly is critical for conditions like these, since once cells or organs are damaged by disease-causing mutations, they can't always be rescued. The idea is to intervene with a CRISPR therapy to minimize the effects that the mutations could have. Currently, about 6,000 rare diseases affect 300 million people worldwide, and 72% of them are linked to genetic aberrations. A similar proportion primarily affect children. The new center will focus on identifying disease-causing mutations that can easily be targeted—such as in the liver, as in KJ's case. 'Jennifer and her team, and the team at UCSF, will be very careful in choosing mutations that are amenable to this treatment,' says Chan. 'Not all mutations will work well with this version of there will be a delicate balance in choosing patients who stand to benefit the most in this situation.' Patients will join a clinical trial to receive the treatment, and the research team will study them to learn from their experiences and continue to improve the treatment and the process. Read More: Why It's So Hard to Have Your Fertility Tested In the first cases that the center will try to treat, the FDA will consider each treatment on its own and decide whether to approve the customized therapy for that particular patient. But, says Doudna, 'as we continue to get more information on the safety and potential risks of CRISPR for different indications, what is emerging is the potential to designate CRISPR as a platform technology.' That means that if regulators approve the framework of the CRISPR gene-editing process, doctors would not need to conduct animal tests for each new CRISPR therapy designed for a patient. The only thing that would change would be the guide RNA, Doudna says, which carries the genetic instructions for finding the specific mutation that needs to be addressed. 'Even there, most of the guide RNA stays the same, and it's just the piece at the end providing the molecular zip code that changes.' Key to making that happen will be advances in other scientific areas, including using AI to predict how changing specific genes will affect a cell's function and what potential health outcomes a CRISPR-based treatment might have. That work is ongoing separately at places like Chan Zuckerberg Initiative and elsewhere, says Chan. Eventually, says Doudna, 'we hope as the process moves forward, it will be possible to both predict clinical outcomes of CRISPR therapies accurately and ensure that by changing just a little part of the guide RNA, everything else will remain the same, so you don't have to do full-blown animal testing for every single iteration of CRISPR. If that becomes possible, then it will make CRISPR a lot cheaper and a lot faster to test these kinds of therapies.' That would make it available for many more patients as well.

DoH, UCSF, IGI explore establishing world's first-of-their kind centres for Genome surgery
DoH, UCSF, IGI explore establishing world's first-of-their kind centres for Genome surgery

Al Etihad

time04-07-2025

  • Health
  • Al Etihad

DoH, UCSF, IGI explore establishing world's first-of-their kind centres for Genome surgery

4 July 2025 18:19 ABU DHABI (ALETIHAD) The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has announced a landmark partnership with the University of California, San Francisco (UCSF) and the Innovative Genomics Institute (IGI) to explore the establishment of the world's first-of-their-kind centres for genome surgery in Abu Dhabi and during a strategic visit to the United States, the collaboration seeks to accelerate the Emirate's efforts to lead in genomic medicine and advance personalised genetic therapy, transforming the future of healthcare delivery for the global community. Genome surgery is an experimental medical technique aimed at modifying or replacing faulty genes within cells to treat or prevent diseases. This is achieved through personalised genetic therapies or by using advanced technologies such as CRISPR, which can be tailored specifically to each patient based on their unique genetic new centres would enable the diagnosis and correction of severe genetic conditions as early as possible to improve outcomes. Leveraging CRISPR-based technologies, the Centres would offer customised, genome-guided interventions that have the potential to transform patient outcomes and redefine the future of Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, commented, 'This collaboration reflects Abu Dhabi's determination to pioneer real-world applications of advanced science. Partnering with UCSF and IGI, one of the world's most respected institutions in gene therapy, would accelerate our ability to integrate genome-guided care into our healthcare system, creating an unprecedented opportunity to correct genetic conditions early in life, prevent chronic disease progression and reduce long-term healthcare costs'.By combining Abu Dhabi's state-of-the-art healthcare infrastructure and genomic data capabilities with UCSF's global leadership in pediatric and fetal therapy and IGI's cutting-edge research in gene editing, the partnership would drive the development and delivery of innovative, real-world solutions for patients with early-onset, severe, rare and inherited Tippi MacKenzie, Director of the UCSF Broad Stem Cell Centre, at University of California, San Francisco (UCSF), said, 'This is an extraordinary time to be in medicine, when we have the opportunity to develop life-saving therapies for patients with severe genetic conditions. "We are excited by the possibility of developing mirrored programmes that coalesce multidisciplinary expertise and link the myriad steps between diagnosing a genetic disease and developing and implementing a safe genome surgery strategy.'The collaboration would also prioritise building national expertise by training a new generation of Emirati professionals in genomic surgery and clinical innovation. By intervening early in life-threatening or debilitating conditions, the initiative would build capacity to support families, reduce dependence on lifelong treatments, and ease pressure on the healthcare system, cementing Abu Dhabi's position as a global destination for advanced genomic care and life sciences Fyodor Urnov, Professor of Molecular Therapeutics at the University of California, Berkeley, and Director of the IGI-Danaher Beacon for CRISPR Cures, said, 'This year marks a landmark achievement for science and medicine of a CRISPR gene-editing therapeutic designed and administered on-demand to an infant with a severe inborn error of metabolism in record time. "The mission of the Innovative Genomics Institute as defined by its founder, Jennifer Doudna, winner of the 2020 Nobel Prize for CRISPR gene editing, is to make it the standard of medical care, no matter where such a child is born. The IGI's deep partnership with Danaher that made an enabling contribution to the on-demand gene edit earlier this year provides an outstanding technological and manufacturing foundation for scaling such therapeutic approaches. "We are honoured to partner with world-leading clinical expertise at UCSF to explore how we may ultimately expand CRISPR on demand to children living with severe genetic diseases in the UAE.'This exploratory partnership aligns with Abu Dhabi's broader vision to embed genomics into public health and drive a shift toward personalised and preventive care. Central to this effort is the Emirati Genome Programme, which has sequenced over 800,000 genomes to date, to create one of the most diverse national databases programme has enabled key initiatives such as the national pharmacogenomics reporting system (PGx), with over 160,000 reports now available to help tailor treatment plans based on individual genetic profiles. Additional milestones include the integration of genetic testing into the Premarital Screening Programme, the launch of the Newborn Genetic Screening Programme, and the development of the Emirati Reference Genome platform. These efforts are supported by the upskilling of over 100 Emirati physicians in genomic medicine and counselling through advanced training initiatives, strengthening local expertise in this critical a significant leap forward, Abu Dhabi introduced CRISPR-Cas9 gene-editing therapy in the UAE for the first time through CASGEVY, a breakthrough treatment for sickle cell disease. Alongside this achievement, the Emirate's Personalised Precision Medicine Programme for oncology, which has delivered tailored care to more than 250 cancer patients. Together, these initiatives underscore Abu Dhabi's commitment to advancing real-world genomic solutions that improve health outcomes and reduce the long-term burden of by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 to 21, delegation conducted over 20 strategic meetings and visits with public and private sector leaders across the US, aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) and startAD.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store